3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Venous Thromboembolism
4
Neoplasms
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombosis
1
Pulmonary Embolism
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Interventions
venetoclax
21
Cyclophosphamide
14
Cytarabine
12
Azacitidine
8
fludarabine
7
Dexamethasone
5
Daunorubicin
5
ruxolitinib
4
revumenib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
quizartinib
3
pirtobrutinib
3
gamma-Globulins
3
fludarabine phosphate
3
blinatumomab
3
Tacrolimus
3
Rituximab
3
Palliative Care
3
Inotuzumab Ozogamicin
3
Granulocyte Colony-Stimulating Factor
3
Decitabine
3
Ciprofloxacin
3
Blood Specimen Collection
3
zanubrutinib
2
ponatinib
2
pembrolizumab
2
ibrutinib
2
aldesleukin
2
acalabrutinib
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia
×
Rivaroxaban
×
Clear all
NCT07270263
2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA
Recruiting
100 enrolled